All News

Heidegger emphasizes that sexual concerns are almost never purely biological or purely psychological—they are biopsychosocial.

The code, J9282, went into effect on January 1, 2026.

According to the authors, these findings support the early use of genomic testing to guide treatment decisions.

"Although social media may not be for every health care worker, I hope that moving forward, more medical content creators will collaborate with the academic medical community to shape the world for the better," writes Maheetha Bharadwaj, MD.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC.

As the year comes to a close, we revisit some of this year’s top content in female urology.

As the year comes to a close, we revisit some of this year’s top content in men's health.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

As the year comes to a close, we revisit some of this year’s top content on genomic testing.

As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025.

Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.

As the year comes to a close, we revisit some of this year’s top content on urology coding and reimbursement.

Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

In this episode, Timothy Daskivich, MD, joins host Adam Weiner, MD, to discuss survivorship and long-term quality-of-life considerations in prostate cancer care.

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

The application is supported by results from the phase 3 PIVOT-PO trial.

The PROSTOX ultra test identifies men with localized prostate cancer who are at a higher risk of developing late GU toxicity from radiation, helping to inform treatment decisions.

The approval is supported by data from the TRITON3 trial.

Patients with GG1 disease and a high genomic classifier score had a significantly higher risk of disease progression.

A key theme throughout the forum was the importance of assessing disease volume and clinical presentation at diagnosis.

The combination yielded significant improvements in event-free survival, overall survival, and pathologic complete response rates vs neoadjuvant chemotherapy.

When discussing treatment goals, clinicians underscored the importance of individualizing systemic therapy.

The combination demonstrated a disease-specific survival rate of 98.7% at 12 months and 96.0% at 36 months.

The safety and efficacy of the Revi System were established in the pivotal OASIS trial.